specificity to exert their suppressive effects are difficult to reconcile with the fact that in most cases neither tumor-bearing mice nor cancer patients are immune compromised (with the exception of terminal stages of the disease). T cells from the blood of cancer patients and from the spleens or lymph nodes of tumor-bearing mice have relatively strong responses to nonspecific stimuli like lectins, anti-CD3 antibody, etc. However, tumor-specific responses of these T cells are substantially inhibited (7) (8) (9) . In contrast, T cells isolated from the tumor site in both patients and mice are profoundly suppressed, exhibiting dramatic changes in T-cell receptor (TCR) signaling, proliferation, and effector functions (10) (11) (12) . This has resulted in the development of the third paradigm in tumor immunology: a compartmentalization of immune suppression in cancer. Immune deficiency at the tumor site is profound and antigen-independent, whereas in the periphery it is much more specialized with respect to tumor-associated antigens.
Additional complications come from the fact that T cell infiltration into solid tumors is limited by the effect of tumor stroma and other factors, which will be discussed below.
We recently proposed new paradigm that may have direct implications for cancer immune therapy: tumor cells may resist recognition by potent CTLs in a way that does not affect immune suppression. This process is mediated by reactive oxygen species (ROS) and reactive nitrogen species (RNS) and is associated with tumor infiltration by myeloid cells (13) .
Myeloid cells in cancer and production of reactive oxygen species
It is now clear that inflammation plays a major role in tumor progression (14) . controlled by an antioxidant system, PNT can cause severe damage by oxidizing biological molecules such as membrane phospholipids, nucleic acids and proteins. In particular, PNT induces the nitration of four aminoacids: tyrosine, cysteine, methionine and tryptophan (31).
Nitrotyrosine in tissues has been used as a marker of PNT activity (32).
The metabolism of L-arginine in myeloid cells is also associated with the production of ROS/RNS. L-arginine acts as a substrate for two enzymes, arginase 1 and Nos2. Arginase 1 converts L-arginine to urea and L-ornithine, and directs the production of superoxide anion, while Nos2 causes the generation of high levels of NO. The cooperative effect of arginase 1 and Nos2 drives the production of PNT (33). PNT has been detected in many cancers, and high PNT levels in tumor tissues are associated with poor prognosis (34-38).
Possible role of PNT in cancer
At least three negative effects of myeloid cell-produced PNT have been demonstrated in the tumor microenvironment (Fig.1 ).
1. PNT can cause T cell suppression and tolerance. Inside the tumor site, high levels of PNT induce the nitration of tumor-infiltrating lymphocytes and render these cells non-responsive to various nonspecific stimuli (39) . In the peripheral lymphoid organs, the level of PNT is much lower. It is produced by myeloid cells, primarily MDSC, and it requires close cell-cell contact between MDSC and T cells to affect T cell function. Macrophages and neutrophils can also produce PNT, albeit at substantially lower levels than MDSC, and potentially can contribute to this effect. PNT can induce T cell tolerance via nitration of the TCRs and CD8 on the surface of T cells, rendering CD8 + T cells unable to bind to peptide-MHC complexes (40 demonstrated no responses to the specific peptides, while non-nitrated CTLs responded normally to the peptide stimulation (9) . However, after interaction with MDSC, T cells retain their ability to respond to nonspecific stimuli. 
